Helmut Butzkueven

List of Publications by Year
in descending order

234 papers	13,072 citations	36271 51 h-index	28275 105 g-index
239 all docs	239 docs citations	239 times ranked	15027 citing authors

#	Article	IF	Citations
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	13.7	2,400
2	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
3	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	3.8	336
4	Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology, 2011, 70, 897-912.	2.8	314
5	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	3.7	281
6	Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S5-S48.	0.9	280
7	LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nature Medicine, 2002, 8, 613-619.	15.2	241
8	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	4.9	219
9	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 189-199.	4.9	210
10	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology, 2021, 97, e1870-e1885.	1.5	168
11	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078.	1.1	166
12	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	3.7	162
13	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	2.8	158
14	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1190-1197.	0.9	156
15	Treatment decisions in multiple sclerosis â€" insights from real-world observational studies. Nature Reviews Neurology, 2017, 13, 105-118.	4.9	154
16	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 739-746.	1.4	148
17	Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	2.8	143
18	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	3.7	140

#	Article	IF	Citations
19	Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 2014, 82, 1204-1211.	1.5	138
20	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	4.9	134
21	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLoS ONE, 2015, 10, e0122686.	1.1	122
22	Prognosticating autoimmune encephalitis: A systematic review. Journal of Autoimmunity, 2019, 96, 24-34.	3.0	115
23	Gas6 Deficiency Increases Oligodendrocyte Loss and Microglial Activation in Response to Cuprizone-Induced Demyelination. Journal of Neuroscience, 2008, 28, 5195-5206.	1.7	114
24	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.5	110
25	Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Autoimmunity Reviews, 2017, 16, 658-665.	2.5	106
26	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	4.5	100
27	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 660-668.	0.9	97
28	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	3.7	94
29	Genetic Dissection of the Human Leukocyte Antigen Region by Use of Haplotypes of Tasmanians with Multiple Sclerosis. American Journal of Human Genetics, 2002, 70, 1125-1137.	2.6	93
30	Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. NeuroImage, 2009, 45, 679-686.	2.1	84
31	The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine, 2016, 14, 81.	2.3	83
32	Vitamin D for the treatment of multiple sclerosis: a meta-analysis. Journal of Neurology, 2018, 265, 2893-2905.	1.8	83
33	Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia, 2006, 53, 696-703.	2.5	82
34	Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia, 2008, 56, 686-698.	2.5	79
35	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis Journal, 2018, 24, 963-973.	1.4	79
36	What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis. Autoimmunity Reviews, 2018, 17, 1202-1209.	2.5	79

#	Article	IF	Citations
37	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1133-1137.	0.9	76
38	MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. NeuroImage, 2007, 37, 1138-1147.	2.1	75
39	Microstructural abnormalities in the trigeminal nerves of patients with trigeminal neuralgia revealed by multiple diffusion metrics. European Journal of Radiology, 2013, 82, 783-786.	1.2	74
40	Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1511-1522.	1.4	73
41	Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7859-7864.	3.3	71
42	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	0.9	71
43	Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Movement Disorders, 2007, 22, 590-591.	2.2	68
44	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Annals of Neurology, 2014, 76, 880-890.	2.8	67
45	Observational data: Understanding the real MS world. Multiple Sclerosis Journal, 2016, 22, 1642-1648.	1.4	67
46	Data quality evaluation for observational multiple sclerosis registries. Multiple Sclerosis Journal, 2017, 23, 647-655.	1.4	64
47	A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations. Multiple Sclerosis Journal, 2012, 18, 1013-1021.	1.4	63
48	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	0.9	63
49	Epigenome-wide association studies: current knowledge, strategies and recommendations. Clinical Epigenetics, 2021, 13, 214.	1.8	62
50	A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Neurology, 2012, 79, 92-99.	1.5	61
51	Nitrous oxide myelopathy in an abuser of whipped cream bulbs. Journal of Clinical Neuroscience, 2000, 7, 73-75.	0.8	57
52	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	1.7	57
53	A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. PLoS ONE, 2010, 5, e13454.	1.1	55
54	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	1.4	55

#	Article	IF	Citations
55	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.5	54
56	A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. Human Molecular Genetics, 2015, 24, 5644-5654.	1.4	53
57	Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle?. Frontiers in Immunology, 2019, 10, 2066.	2.2	53
58	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	1.4	52
59	Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade. , 2010, 126, 82-93.		51
60	COVID-19 in people with multiple sclerosis: A global data sharing initiative. Multiple Sclerosis Journal, 2020, 26, 1157-1162.	1.4	50
61	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	0.9	49
62	Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2008, 86, 3548-3555.	1.3	46
63	Brain plasticity in relapsingâ€"remitting multiple sclerosis: Evidence from resting-state fMRI. Journal of the Neurological Sciences, 2011, 304, 127-131.	0.3	46
64	Multiple Sclerosis Susceptibility-Associated SNPs Do Not Influence Disease Severity Measures in a Cohort of Australian MS Patients. PLoS ONE, 2010, 5, e10003.	1.1	45
65	A role for galanin in human and experimental inflammatory demyelination. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15466-15471.	3.3	44
66	Diffusion tensor imaging of the optic radiations after optic neuritis. Human Brain Mapping, 2012, 33, 2047-2061.	1.9	44
67	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619.	4.9	44
68	Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2015, 2, 479-491.	1.7	43
69	Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. Acta Neuropathologica, 2019, 138, 443-456.	3.9	41
70	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.5	41
71	Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. Human Genetics, 2004, 114, 573-580.	1.8	40
72	Optic Nerve Diffusion Tensor Imaging after Acute Optic Neuritis Predicts Axonal and Visual Outcomes. PLoS ONE, 2013, 8, e83825.	1.1	40

#	Article	IF	Citations
73	Neurofilament Proteins as Body Fluid Biomarkers of Neurodegeneration in Multiple Sclerosis. Multiple Sclerosis International, 2011, 2011, 1-7.	0.4	38
74	The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. PLoS ONE, 2013, 8, e59694.	1.1	38
75	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.5	38
76	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs, 2018, 32, 1159-1171.	2.7	38
77	Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor. Journal of Neuroscience Research, 2000, 59, 712-721.	1.3	37
78	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310.	0.9	37
79	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	1.4	37
80	Altered Topological Organization of White Matter Structural Networks in Patients with Neuromyelitis Optica. PLoS ONE, 2012, 7, e48846.	1.1	37
81	Diffusion Tensor Imaging Correlates of Visual Impairment in Multiple Sclerosis and Chronic Optic Neuritis. , 2012, 53, 825.		36
82	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	1.4	36
83	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	1.4	36
84	Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. Journal of Clinical Neuroscience, 2007, 14, 1126-1129.	0.8	35
85	What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?. International Journal of Molecular Sciences, 2012, 13, 12665-12709.	1.8	35
86	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.3	35
87	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	0.9	35
88	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	1.1	35
89	Cortical Thinning Correlates with Cognitive Change in Multiple Sclerosis but not in Neuromyelitis Optica. European Radiology, 2014, 24, 2334-2343.	2.3	34
90	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	1.4	34

#	Article	IF	Citations
91	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	2.8	34
92	The MSBase registry: Informing clinical practice. Multiple Sclerosis Journal, 2019, 25, 1828-1834.	1.4	34
93	The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function. PLoS ONE, 2015, 10, e0127080.	1.1	34
94	Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	0.8	33
95	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple Sclerosis Journal, 2021, 27, 1543-1555.	1.4	33
96	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	3.7	32
97	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	1.4	30
98	Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2013, 1, 32.	2.4	29
99	Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores ≤3.0. NeuroRehabilitation, 2017, 40, 277-284.	0.5	29
100	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	0.9	29
101	Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status. PLoS Genetics, 2016, 12, e1005853.	1.5	29
102	Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. Journal of Neuroimmunology, 2009, 211, 105-109.	1.1	28
103	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	1.1	27
104	Vaginally Administered PEGylated LIF Antagonist Blocked Embryo Implantation and Eliminated Non-Target Effects on Bone in Mice. PLoS ONE, 2011, 6, e19665.	1.1	26
105	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. PLoS ONE, 2013, 8, e63480.	1.1	26
106	Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641880476.	1.5	26
107	Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. Journal of Clinical Investigation, 2014, 124, 5042-5056.	3.9	26
108	EphA4 Receptor Tyrosine Kinase Is a Modulator of Onset and Disease Severity of Experimental Autoimmune Encephalomyelitis (EAE). PLoS ONE, 2013, 8, e55948.	1.1	25

#	Article	IF	Citations
109	Leukemia Inhibitory Factor Protects Axons in Experimental Autoimmune Encephalomyelitis via an Oligodendrocyte-Independent Mechanism. PLoS ONE, 2012, 7, e47379.	1.1	24
110	Tremor in multiple sclerosis is associated with cerebello-thalamic pathology. Journal of Neural Transmission, 2017, 124, 1509-1514.	1.4	24
111	Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. European Radiology, 2018, 28, 96-103.	2.3	24
112	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	3.7	24
113	Altered thalamic functional connectivity in multiple sclerosis. European Journal of Radiology, 2015, 84, 703-708.	1.2	23
114	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Multiple Sclerosis Journal, 2021, 27, 465-474.	1.4	23
115	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. Journal of Clinical Neuroscience, 2014, 21, 1847-1856.	0.8	22
116	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	0.9	22
117	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.3	22
118	Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis. Cerebellum, 2020, 19, 691-700.	1.4	22
119	Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells. Life Science Alliance, 2020, 3, e202000650.	1.3	22
120	Parallel Changes in Structural and Functional Measures of Optic Nerve Myelination after Optic Neuritis. PLoS ONE, 2015, 10, e0121084.	1.1	21
121	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. JAMA Neurology, 2020, 77, 1496.	4.5	21
122	A genetic basis for multiple sclerosis severity: Red herring or real?. Molecular and Cellular Probes, 2016, 30, 357-365.	0.9	20
123	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology, 2018, 75, 1407.	4.5	20
124	Head-to-head drug comparisons in multiple sclerosis. Neurology, 2019, 93, 793-809.	1.5	20
125	On the utility of data from the International HapMap Project for Australian association studies. Human Genetics, 2006, 119, 220-222.	1.8	19
126	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. Journal of Clinical Neuroscience, 2014, 21, 1857-1865.	0.8	19

#	Article	IF	Citations
127	Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study. Health and Quality of Life Outcomes, 2013, 11, 127.	1.0	18
128	Continuing fingolimod after development of macular edema: A case report. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e13.	3.1	18
129	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	1.4	18
130	Monoclonal antibodies in the treatment of multiple sclerosis: emergence of Bâ€cellâ€targeted therapies. British Journal of Pharmacology, 2017, 174, 1895-1907.	2.7	17
131	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders, 2018, 24, 11-19.	0.9	17
132	MSCOVID19: Using social media to achieve rapid dissemination of health information. Multiple Sclerosis and Related Disorders, 2020, 45, 102338.	0.9	17
133	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	1.8	17
134	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Frontiers in Neurology, 2021, 12, 647811.	1.1	17
135	Clinical isolated syndrome: A 3-year follow-up study in China. Clinical Neurology and Neurosurgery, 2011, 113, 658-660.	0.6	16
136	Optic Nerve Magnetisation Transfer Ratio after Acute Optic Neuritis Predicts Axonal and Visual Outcomes. PLoS ONE, 2012, 7, e52291.	1.1	16
137	Serial Diffusion Tensor Imaging of the Optic Radiations after Acute Optic Neuritis. Journal of Ophthalmology, 2016, 2016, 1-6.	0.6	16
138	Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ Open, 2020, 10, e038861.	0.8	16
139	Developing a Digital Solution for Remote Assessment in Multiple Sclerosis: From Concept to Software as a Medical Device. Brain Sciences, 2021, 11, 1247.	1.1	16
140	Baseline brain activity changes in patients with clinically isolated syndrome revealed by resting-state functional MRI. Acta Radiologica, 2012, 53, 1073-1078.	0.5	15
141	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. Journal of Clinical Neuroscience, 2014, 21, 1835-1846.	0.8	15
142	Multimodal characterization of gray matter alterations in neuromyelitis optica. Multiple Sclerosis Journal, 2018, 24, 1308-1316.	1.4	15
143	The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. Neurotherapeutics, 2020, 17, 1768-1784.	2.1	15
144	Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis. British Journal of Pharmacology, 2020, 177, 4113-4133.	2.7	15

#	Article	IF	Citations
145	Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Multiple Sclerosis Journal, 2021, 27, 719-728.	1.4	15
146	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, e869-e880.	1.5	15
147	Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium. Frontiers in Immunology, 2020, 11, 597858.	2.2	14
148	Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. Immunogenetics, 2007, 59, 177-186.	1.2	13
149	Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor. Glia, 2015, 63, 1005-1020.	2.5	13
150	The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641985918.	1.5	13
151	Seizures in autoimmune encephalitis: Kindling the fire. Epilepsia, 2020, 61, 1033-1044.	2.6	13
152	Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis. Autoimmunity Reviews, 2022, 21, 103057.	2.5	13
153	Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731664170.	0.5	11
154	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	1.4	11
155	Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis. Journal of Neuroimmunology, 2021, 353, 577508.	1.1	11
156	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. European Journal of Neurology, 2022, 29, 1082-1090.	1.7	11
157	Lesion Volume in Relapsing Multiple Sclerosis is Associated with Perivascular Space Enlargement at the Level of the Basal Ganglia. American Journal of Neuroradiology, 2022, 43, 238-244.	1.2	11
158	Association of plasma levels of Protein S with disease severity in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731559653.	0.5	10
159	A new era in the treatment of multiple sclerosis. Medical Journal of Australia, 2015, 203, 139-141.	0.8	10
160	Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 696-705.	1.4	10
161	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. Multiple Sclerosis Journal, 2020, 26, 1765-1774.	1.4	10
162	Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2021, 47, 102642.	0.9	10

#	Article	IF	Citations
163	Genotype and Phenotype in Multiple Sclerosisâ€"Potential for Disease Course Prediction?. Current Treatment Options in Neurology, 2018, 20, 18.	0.7	9
164	High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199891.	1.5	9
165	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067.	0.3	9
166	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity scoreâ€"matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110424.	1.5	9
167	Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients. Scientific Reports, 2020, 10, 22217.	1.6	9
168	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLoS ONE, 2016, 11, e0144834.	1.1	8
169	Silent lesions on MRI imaging â€" Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	1.4	8
170	Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod. Ophthalmology, 2019, 126, 438-444.	2.5	8
171	Validation of a precision tremor measurement system for multiple sclerosis. Journal of Neuroscience Methods, 2019, 311, 377-384.	1.3	8
172	The effectiveness of natalizumab vs fingolimodâ€"A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	0.9	8
173	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	2.7	8
174	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	1.1	8
175	Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 2022, 42, 355-364.	1.1	8
176	Common variation in the MOG gene influences transcript splicing in humans. Journal of Neuroimmunology, 2010, 229, 225-231.	1.1	7
177	Novel Functional MRI Task for Studying the Neural Correlates of Upper Limb Tremor. Frontiers in Neurology, 2018, 9, 513.	1.1	7
178	Vitamin D status in an Australian patient population: a large retrospective case series focusing on factors associated with variations in serum 25(OH)D. BMJ Open, 2020, 10, e032567.	0.8	7
179	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri Â® Observational Program (TOP). Multiple Sclerosis Journal, 2021, 27, 410-419.	1.4	7
180	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	1.4	7

#	Article	IF	Citations
181	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 2021, 97, e2020-e2031.	1.5	7
182	Galanin in Glia: Expression and Potential Roles in the CNS. Exs, 2010, 102, 61-69.	1.4	6
183	The role of vitamin D and P2X7R in multiple sclerosis. Journal of Neuroimmunology, 2019, 330, 159-169.	1.1	6
184	Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732095735.	0.5	6
185	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
186	The MSBase pregnancy, neonatal outcomes, and women's health registry. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110091.	1.5	6
187	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 831-841.	1.4	6
188	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	1.4	6
189	Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides. Autoimmunity Reviews, 2022, 21, 103074.	2.5	6
190	Prospects for stem cell transplantation in multiple sclerosis. Journal of Clinical Neuroscience, 2002, 9, 361-367.	0.8	5
191	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731560019.	0.5	5
192	Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study. Molecular Medicine, 2018, 24, 27.	1.9	5
193	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	1.4	5
194	Combined peripheral nerve and central nervous system demyelination in a patient with chronic inflammatory demyelinating polyneuropathy. Journal of Clinical Neuroscience, 1999, 6, 358-360.	0.8	4
195	Prognosis in autoimmune encephalitis: Database. Data in Brief, 2018, 21, 2694-2703.	0.5	4
196	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). JMIR Research Protocols, 2021, 10, e24969.	0.5	4
197	The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets. Current Medical Research and Opinion, 2022, 38, 1167-1176.	0.9	4
198	Neuroglial responses to CNS injury: prospects for novel therapeutics. Expert Review of Neurotherapeutics, 2004, 4, 869-878.	1.4	3

#	Article	IF	Citations
199	Commentary on â€œPossible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injectionâ€. Journal of Clinical Neuroscience, 2013, 20, 312-313.	0.8	3
200	Genetic Predisposition, Humans. , 2014, , 341-364.		3
201	Ceruloplasmin geneâ€deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution. Journal of Neuroscience Research, 2014, 92, 732-742.	1.3	3
202	OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas. Multiple Sclerosis and Related Disorders, 2020, 40, 101984.	0.9	3
203	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	1.4	3
204	Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.. Multiple Sclerosis and Related Disorders, 2022, 58, 103393.	0.9	3
205	Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITIONâ€A 2-Year, Multicenter, Observational, Cohort Study. Brain Sciences, 2022, 12, 215.	1.1	3
206	Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. BMC Neurology, 2022, 22, 84.	0.8	3
207	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	1.7	3
208	Psychometric deficits in autoimmune encephalitis: A retrospective study from the Australian Autoimmune Encephalitis Consortium. European Journal of Neurology, 2022, 29, 2355-2366.	1.7	3
209	Immunosuppressive therapy is valuable in aggressive Multiple Sclerosis. Journal of Clinical Neuroscience, 2000, 7, 561-563.	0.8	2
210	Early imaging predictors of longer term multiple sclerosis risk and severity in acute optic neuritis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731986312.	0.5	2
211	Electroclinical biomarkers of autoimmune encephalitis. Epilepsy and Behavior, 2022, 128, 108571.	0.9	2
212	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	1.4	2
213	Multiple Sclerosis: A Haplotype Association Study. Novartis Foundation Symposium, 2008, , 31-45.	1.2	1
214	Anti-Aquaporin-4 Antibody Positivity in Neuromyelitis Optica Is Associated with Lesion Activity. European Neurology, 2013, 70, 113-116.	0.6	1
215	A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data. Journal of Visualized Experiments, 2015, , e53169.	0.2	1
216	Is my MS patient failing treatment?. Neurology, 2016, 87, 124-125.	1.5	1

#	Article	IF	Citations
217	Vitamin D in the treatment of multiple sclerosis: A meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.95-e1.	0.9	1
218	Obesity and brain volume loss in multiple sclerosis. Neurology, 2018, 91, 1079-1080.	1.5	1
219	002â€¦Therapeutic lag in relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A1.2-A1.	0.9	1
220	The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102212.	0.9	1
221	008â€¦Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. , 2021, , .		1
222	Quantifying the impact of upper limb tremor on the quality of life of people with multiple sclerosis: a comparison between the QUEST and MSIS-29 scales. Multiple Sclerosis and Related Disorders, 2022, 58, 103495.	0.9	1
223	Longitudinal tracking of axonal loss using diffusion magnetic resonance imaging in multiple sclerosis. Brain Communications, 2022, 4, fcac065.	1.5	1
224	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	1.7	1
225	Reply to â€œIs there sentinel demyelination before development of primary CNS lymphoma?â€ Journal of Clinical Neuroscience, 2008, 15, 1071-1072.	0.8	0
226	Paraclinical Correlates of Visual Acuity Loss in Multiple Sclerosis. Journal of Clinical Neuroscience, 2009, 16, 1521-1522.	0.8	0
227	Neurodegeneration in MS and NMO: The Eye and the Blood. Multiple Sclerosis International, 2011, 2011, 1-2.	0.4	0
228	JC virus conversion rates in natalizumab treated patients: the melbourne longitudinal cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.15-e1.	0.9	0
229	Reply to: Comment on Y.D. Fragoso et al.: â€œLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodâ€[Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	0.9	0
230	085â€¦Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri$^®$ observational program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A34.2-A34.	0.9	0
231	086â€¦The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A35.1-A35.	0.9	0
232	004â€¦Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
233	006â€¦Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models. , 2021, , .		0
234	Comprehensive clinical, radiological, pathological and biochemical analysis required to differentiate VV1 sporadic Creutzfeldt-Jakob disease from suspected variant CJD. BMJ Neurology Open, 2022, 4, e000299.	0.7	0